How effective is ribociclib in cancer treatment?

Ribociclib (Ribociclib), as an innovative CDK4/6 inhibitor, has become a treatment for hormone receptor-positive (H It is an important drug for advanced breast cancer with R+) and human epidermal growth factor receptor 2 negative (HER2-). The evaluation of its efficacy mostly relies on rigorous clinical trial data.

In numerous pivotal clinical trials, the combination of ribociclib and hormone therapy has demonstrated superior therapeutic effects compared to hormone therapy alone. For example, in clinical trials such as MONALEESA-2, -3 and -7, the progression-free survival of the patient group treated with ribociclib (ribociclib) was significantly longer than that of the patient group who only received placebo.

In the MONALEESA-2 clinical trial, ribociclib (ribociclib) combined with a steroid hormone was more effective than a combination of placebo and steroid hormonesHR+, HER2- advanced breast cancer had a median extension of progression-free survival of approximately 10 months. The results of the MONALEESA-3 trial are similar. The combination of ribociclib (ribociclib) and systemic hormone therapy can also significantly extend the median progression-free survival of these patients, which is about 8 months. Furthermore, data from the MONALEESA-7 trial show that this combination treatment regimen is also suitable for a broader patient population, including premenopausal women.

In summary,Riboxiclib (Riboxiclib) has shown satisfactory efficacy in the treatment ofHR+, HER2- advanced breast cancer, and its effective rate is relatively high. However, it is worth noting that the specific effectiveness rate will vary due to differences in patient characteristics, treatment options, and clinical trial designs. Therefore, the final treatment effect needs to be determined based on the patient's actual condition and the doctor's comprehensive evaluation.